Bio­Marin looks for fast ap­proval of he­mo­phil­ia A gene ther­a­py; In­ves­ti­ga­tors tout En­ta­sis an­tibi­ot­ic

→ Bio­Marin $BM­RN told an­a­lysts dur­ing its R&D day that new FDA rules may make it pos­si­ble to file for an FDA ap­proval on its he­mo­phil­ia A gene ther­a­py val­rox, if the Phase I/II study con­tin­ues as ex­pect­ed.

→ In­ves­ti­ga­tors in­volved in a Phase II study of a new an­tibi­ot­ic say that a sin­gle oral dose worked in treat­ing gon­or­rhea. Zo­liflo­dacin — de­vel­oped by En­ta­sis — works by in­hibit­ing DNA biosyn­the­sis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER